ANALYSIS
This contract-research firm began a new phase in 2004 when it acquired PharmaNet, a specialist in late-stage research, adding to the early-phase trial data it provides drugmakers.
Rank
Revenue ($ millions, four quarters to 12/31/04)
159.6
--
Revenue growth (%, 3-year annual rate)
73.8
7
Net income ($ millions, four quarters to 12/31/04)
These companies represent the fifth graduating class of the annual FSB 100. They
have been screened just as the others were: Zacks, a financial research firm, identified companies with annual revenue of less than $200 million and a stock price of more than $1 and ranked them based on the past three years' earnings growth, revenue growth, and stock performance. We excluded banks and real estate firms, which would otherwise overrun the list.
How we pick the 25 richest executives
Call them mini-Buffetts: the executives who hold major stakes in their companies on the FSB 100 list. We hired Equilar, an executive-compensation research firm in San Mateo, Calif., to identify them and review the proxy statements of every
company on the list. The numbers below include all shares of stock owned outright, plus all vested options. (We ignored options that haven't vested.) Please, no hitting these folks up for loans.
